People

Promethera® is strategically advised by a distinguished international board of directors to drive us towards our goal of being the global leader in innovative cell therapies for liver diseases.

BOARD OF DIRECTORS

Etienne Sokal – MD, PhD

Founder
Full Professor at UCLouvain
Chairman of the Board of Directors

30 years experience in the field of hepatology and liver transplantation. Professor Sokal is the founder of Promethera® and co-inventor of HepaStem®. He is full Professor at UCLouvain and a member of the Royal Academy of Medicine of Belgium and of various stem cell and liver scientific societies and is a regular speaker at national and international conferences. He has published over 420 peer-reviewed articles (google scholar h-index of 79)

Reiko Namikawa – MD, PhD

Director

Edward Haack

Director
Chairman of the Audit Committee
Itochu Corporation

Shintaro Hayashi

Director
Co-High

Alick Dong

Director
Hao Tian

Chi Tak Fok

Director
AQ Invest SPRL

Alain Parthoens

Director

EXECUTIVE COMMITTEE

Promethera® has attracted an experienced management team of international experts.

Etienne Sokal – MD, PhD

Founder
Full Professor at UCLouvain
Chairman of the Board of Directors

30 years experience in the field of hepatology and liver transplantation. Professor Sokal is the founder of Promethera® and co-inventor of HepaStem®. He is full Professor at UCLouvain and a member of the Royal Academy of Medicine of Belgium and of various stem cell and liver scientific societies and is a regular speaker at national and international conferences. He has published over 420 peer-reviewed articles (google scholar h-index of 79)

Alain Parthoens

Vesalius Biocapital Managing Partner
Promethera Director of the Board

20+ years of international experience in food and life sciences businesses, 15 years’ experience in venture capital. He led 30 investments in early and neglected late-stage companies. Director at Ogeda, Profibrix, Voluntis, NCardia (ex-Pluriomics), Epics Therapeutics and Promethera®

Alick Dong

Co-High Managing Director
Promethera Director of the Board

More than 10 years of equity investment experience in the fields of healthcare, technology, new consumption, pan-entertainment, energy and infrastructure. He has been involved in investments and exit projects totalled over 1Billion USD.

MANAGEMENT TEAM

ADVISORY BOARD

Promethera®scientific strategy is based on the advice of a distinguished panel of international experts in cell therapy and liver disease.